Cargando…

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

BACKGROUND: PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed strong antitumor activity in preclinical models of cisplatin-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poveda, A., del Campo, J. M., Ray-Coquard, I., Alexandre, J., Provansal, M., Guerra Alía, E. M., Casado, A., Gonzalez-Martin, A., Fernández, C., Rodriguez, I., Soto, A., Kahatt, C., Fernández Teruel, C., Galmarini, C. M., Pérez de la Haza, A., Bohan, P., Berton-Rigaud, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452066/ https://www.ncbi.nlm.nih.gov/pubmed/28368437 http://dx.doi.org/10.1093/annonc/mdx111

Ejemplares similares

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
por: Calvo, E., et al.
Publicado: (2017)

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
por: Takahashi, Ryoko, et al.
Publicado: (2016)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain
por: Ojeda, B, et al.
Publicado: (2003)

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo
por: Chernyshova, Irina A., et al.
Publicado: (2022)

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.
por: Mainwaring, P. N., et al.
Publicado: (1997)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

Influence of Tyrosyl-DNA Phosphodiesterase 1 Inhibitor on the Proapoptotic and Genotoxic Effects of Anticancer Agent Topotecan
por: Chepanova, A. A., et al.
Publicado: (2023)

Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
por: Vukovic, V., et al.
Publicado: (1997)

Assessment of Anti-Cytogenotoxic Effects of Quercetin in Animals Treated with Topotecan
por: Bakheet, Saleh A.
Publicado: (2011)

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
por: Jonsson, E., et al.
Publicado: (1997)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics
por: Nagourney, R A, et al.
Publicado: (2003)

Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma
por: Shackleford, Gregory M., et al.
Publicado: (2019)

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer
por: Levitt, N C, et al.
Publicado: (2005)

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.
por: Pratesi, G., et al.
Publicado: (1995)

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis
por: Léger, F, et al.
Publicado: (2004)

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
por: Penson, R T, et al.
Publicado: (2005)

Adamantane-Monoterpenoid Conjugates Linked via Heterocyclic Linkers Enhance the Cytotoxic Effect of Topotecan
por: Munkuev, Aldar A., et al.
Publicado: (2022)

Tracking the cell cycle origins for escape from topotecan action by breast cancer cells
por: Feeney, G P, et al.
Publicado: (2003)

Intra‐CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases
por: Jaeckle, Kurt A., et al.
Publicado: (2020)

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group
por: Heudel, P-E, et al.
Publicado: (2017)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
por: Kerklaan, B Milojkovic, et al.
Publicado: (2015)

Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer
por: Kuehl, Philip J., et al.
Publicado: (2021)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Development, Characterization, and Evaluation of SLN-Loaded Thermoresponsive Hydrogel System of Topotecan as Biological Macromolecule for Colorectal Delivery
por: Xing, R., et al.
Publicado: (2021)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Development and Validation of an HPLC Method for Analysis of Topotecan in Human Cerebrospinal Fluid and Its Application in Elimination Evaluation of Topotecan after Intraventricular Injection
por: Yoshikawa, Naoki, et al.
Publicado: (2021)

Topotecan in the treatment of relapsed small cell lung cancer
por: Quoix, Elisabeth
Publicado: (2008)

Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
por: Francis, Jasmine H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4d7ptiqu9rjt0rn9h25aokl1i4